ARVO 2026 | May 3-7 | Denver, CO | Booth # 5058
The CRO Built for
Ocular Biologics.
Mosaic Biosciences is an end-to-end protein engineering and drug discovery partner, with deeper experience in ophthalmology than almost any CRO in the space. Meet us at ARVO 2026 and bring your program.
ARVO EXCLUSIVE:
10% off your first discovery engagement for new programs initiated at ARVO 2026.
We Solved the Durability Problem
in Intravitreal Biologics.
Frequent injections limit real-world efficacy. Making molecules bigger extends vitreous half-life but sacrifices the tissue penetration you need. Mosaic’s PKE platform threads the needle: a small engineered peptide that dramatically increases hydrodynamic radius while preserving retinal access and full biological activity.
~2-3x
Increase in hydrodynamic radius, molecules that behave far larger than their actual size.
~2x
Vitreous half-life extension demonstrated in rabbit PK studies, predictive of human performance.
Maintained
Retinal tissue penetration and binding activity — no efficacy trade-off.
Everything You Need to Build
a Protein Therapeutic.
From antibody discovery through IND-enabling studies, under one roof, with one team, and full scientific accountability at every stage.
Antibody Discovery & Optimization
Phage and yeast display platforms plus exclusive access to the Abtherics humanized mouse, full human antibody diversity, in vivo.
Protein Design & Engineering
Half-life extension, bispecific design, affinity maturation, and our proprietary PKE platform for long-acting ocular biologics.
End-to-End Discovery
Bring us a target, an idea, or a molecule at any stage. We provide the strategy, the scientists, and the labs, through clinical candidate.
We Know This Space.
Ophthalmology is our highest-volume therapeutic area by design. We’ve partnered with leading ocular biopharma companies on some of the field’s most technically demanding programs.
Ocular Therapeutix
Discovery collaboration engineering novel complement inhibitors for dry age-related macular degeneration.
Ingenia Therapeutics
Optimization and ARVO 2022 data presentation for IGT-427, a bispecific antibody targeting VEGF and Tie-2 for DME and wet AMD.
Catalyst Biosciences
Collaboration on CB2782, a pegylated complement inhibitor for dry AMD, with preclinical data presented at ARVO.
Let’s Talk About
Your Program.
Book time with our team at ARVO 2026, or fill out the form below to lock in your 10% discount, exclusively for ARVO 2026 attendees.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
VP Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Start a conversation with our scientific team about your discovery program today
Built by Scientists. Proven by Results.
Decades of combined experience in antibody and protein engineering, applied to every program we take on.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.